State Street’s Metagenomi Therapeutics MGX Stock Holding History

State Street’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$143K	Sell	119,850 -577	-0.5%	-$772	﹤0.01%	3905
2026 Q1	$161K	Hold	120,427	–	–	﹤0.01%	3941
2025 Q4	$195K	Sell	120,427 -1,110	-0.9%	-$2.4K	﹤0.01%	3907
2025 Q3	$288K	Sell	121,537 -9,273	-7%	-$18.8K	﹤0.01%	3804
2025 Q2	$194K	Sell	130,810 -436,117	-77%	-$683K	﹤0.01%	3846
2025 Q1	$771K	Buy	566,927 +137,023	+32%	+$326K	﹤0.01%	3483
2024 Q4	$1.55M	Buy	429,904 +399,160	+1,298%	+$963K	﹤0.01%	3389
2024 Q3	$66.7K	Buy	30,744 +270	+0.9%	+$937	﹤0.01%	4052
2024 Q2	$124K	Buy	+30,474	New	+$209K	﹤0.01%	3946

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street's MGX Position: Q2 2026 in Review

State Street reduced its Metagenomi Therapeutics (MGX) stake by 0.48% in Q2 2026, selling an estimated $772 and leaving 119,850 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #3905.

State Street first reported a position in MGX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.55M in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

State Street held 119,850 shares of Metagenomi Therapeutics worth $143K as of Q2 2026.
State Street sold 577 Metagenomi Therapeutics shares in Q2 2026, an estimated $772.
Metagenomi Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3905 holding.
State Street first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 9 quarters since.
State Street's Metagenomi Therapeutics position peaked at $1.55M in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.